Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Calcitonin administration in X-linked hypophosphatemia.

Literature DB >> 21524226

Calcitonin administration in X-linked hypophosphatemia.

Eva S Liu, Thomas O Carpenter, Caren M Gundberg, Christine A Simpson, Karl L Insogna.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 21524226 PMCID： PMC3162370 DOI： 10.1056/NEJMc1010928

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

× No keyword cloud information.

3 in total

1. Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes.

Authors: J H Gooi; S Pompolo; M A Karsdal; N H Kulkarni; I Kalajzic; S H M McAhren; B Han; J E Onyia; P W M Ho; M T Gillespie; N C Walsh; L Y Chia; J M W Quinn; T J Martin; N A Sims
Journal: Bone Date: 2010-02-24 Impact factor: 4.398

2. Normal calcitonin stimulation of serum calcitriol in patients with X-linked hypophosphatemic rickets.

Authors: M J Econs; B Lobaugh; M K Drezner
Journal: J Clin Endocrinol Metab Date: 1992-08 Impact factor: 5.958

3. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling.

Authors: Gerben van Boekel; Janneke Ruinemans-Koerts; Frank Joosten; Paul Dijkhuizen; Adriaan van Sorge; Hans de Boer
Journal: Eur J Endocrinol Date: 2008-03 Impact factor: 6.664

3 in total

15 in total

Review 1. The expanding family of hypophosphatemic syndromes.

Authors: Thomas O Carpenter
Journal: J Bone Miner Metab Date: 2011-12-14 Impact factor: 2.626

Review 2. Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).

Authors: Emily G Farrow; Erik A Imel; Kenneth E White
Journal: Best Pract Res Clin Rheumatol Date: 2011-10 Impact factor: 4.098

Review 3. FGF23 and Phosphate Wasting Disorders.

Authors: Xianglan Huang; Yan Jiang; Weibo Xia
Journal: Bone Res Date: 2013-06-28 Impact factor: 13.567

Review 4. Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.

Authors: Bracha K Goldsweig; Thomas O Carpenter
Journal: Curr Osteoporos Rep Date: 2015-04 Impact factor: 5.096

Review 5. Rickets.

Authors: M Zulf Mughal
Journal: Curr Osteoporos Rep Date: 2011-12 Impact factor: 5.096

Calcitonin administration in X-linked hypophosphatemia.

1. Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes.

2. Normal calcitonin stimulation of serum calcitriol in patients with X-linked hypophosphatemic rickets.

3. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling.

Review 1. The expanding family of hypophosphatemic syndromes.

Review 2. Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).

Review 3. FGF23 and Phosphate Wasting Disorders.

Review 4. Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.

Review 5. Rickets.

Review 6. The changing face of hypophosphatemic disorders in the FGF-23 era.

Review 7. Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.

Review 8. Intestinal phosphate transport: a therapeutic target in chronic kidney disease and beyond?

9. Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia.

Review 10. Pharmacological management of X-linked hypophosphataemia.